Geode Capital Management
ODTX icon

Geode Capital Management’s Odyssey Therapeutics ODTX Stock Holding History

Geode Capital Management’s Portfolio ODTX Stock Details ODTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.45M Buy
425,371
+235,883
+124% +$5.01M ﹤0.01% 2517
2026
Q2 		$3.55M Buy
+189,488
New +$3.32M ﹤0.01% 3050

Other funds holding ODTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Lightspeed Management Company
Lightspeed Management Company Menlo Park, California $2.03B AUM 10.68% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Sands Capital Ventures
Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Geode Capital Management's ODTX Position: Q3 2026 in Review

Geode Capital Management increased its Odyssey Therapeutics (ODTX) stake by 124% in Q3 2026, buying an estimated $5.01M and bringing the position to 425,371 shares worth $9.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2517.

Geode Capital Management first reported a position in ODTX in Q2 2026 and has held it in 2 quarters since. 41 funds tracked by Wall St. Rank hold ODTX as of Q3 2026.

  • Geode Capital Management held 425,371 shares of Odyssey Therapeutics worth $9.45M as of Q3 2026.
  • Geode Capital Management bought 235,883 Odyssey Therapeutics shares in Q3 2026, an estimated $5.01M.
  • Odyssey Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #2517 holding.
  • Geode Capital Management first reported a position in Odyssey Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 41 funds tracked by Wall St. Rank held Odyssey Therapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.